Biomarkers and 3D models predicting response to immune checkpoint blockade in head and neck cancer (Review)

Mandal R, Şenbabaoğlu Y, Desrichard A, Havel JJ, Dalin MG, Riaz N, Lee KW, Ganly I, Hakimi AA, Chan TA and Morris LG: The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight. 1:e898292016. View Article : Google Scholar : PubMed/NCBI

Xu Q, Wang C, Yuan X, Feng Z and Han Z: Prognostic value of tumor-infiltrating lymphocytes for patients with head and neck squamous cell carcinoma. Transl Oncol. 10:10–16. 2017. View Article : Google Scholar

Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264. 2012. View Article : Google Scholar : PubMed/NCBI

Koeck S, Kern J, Zwierzina M, Gamerith G, Lorenz E, Sopper S, Zwierzina H and Amann A: The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3⁺CD8⁺ tumor infiltrating lymphocyte subpopulations. Oncoimmunology. 6:e13236172017. View Article : Google Scholar

Szturz P and Vermorken JB: Translating KEYNOTE-048 into practice recommendations for head and neck cancer. Ann Transl Med. 8:9752020. View Article : Google Scholar : PubMed/NCBI

Pai SI, Zandberg DP and Strome SE: The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. Oral oncol. 61:152–158. 2016. View Article : Google Scholar : PubMed/NCBI

Sun C, Mezzadra R and Schumacher TN: Regulation and Function of the PD-L1 Checkpoint. Immunity. 48:434–452. 2018. View Article : Google Scholar : PubMed/NCBI

Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, et al: Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin Cancer Res. 21:870–881. 2015. View Article : Google Scholar

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI

van Elsas A, Hurwitz AA and Allison JP: Combination immunotherapy of B16 melanoma using anti-cytotoxic T lympho-cyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 190:355–366. 1999. View Article : Google Scholar : PubMed/NCBI

Krummel MF and Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 182:459–465. 1995. View Article : Google Scholar : PubMed/NCBI

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, et al: Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase ib KEYNOTE-012 expansion cohort. J Clin Oncol. 34:3838–3845. 2016. View Article : Google Scholar : PubMed/NCBI

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): An open-label, multicentre, phase 1b trial. Lancet Oncol. 17:956–965. 2016. View Article : Google Scholar : PubMed/NCBI

Soulieres D, Cohen E, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al: Abstract CT115: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma. Cancer Res. 78:CT1152018.

Economopoulou P, Agelaki S, Perisanidis C, Giotakis E and Psyrri A: The promise of immunotherapy in head and neck squamous cell carcinoma. Ann Oncol. 27:1675–1685. 2016. View Article : Google Scholar : PubMed/NCBI

Hsieh JC, Wang HM, Wu MH, Chang KP, Chang PH, Liao CT and Liau CT: Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy. Head Neck. 41(Suppl 1): S19–S45. 2019. View Article : Google Scholar

Lee TW, Lai A, Harms JK, Singleton DC, Dickson BD, Macann AMJ, Hay MP and Jamieson SMF: Patient-Derived xenograft and organoid models for precision medicine targeting of the tumour microenvironment in head and neck cancer. Cancers (Basel). 12:37432020. View Article : Google Scholar

Sailer V, Gevensleben H, Dietrich J, Goltz D, Kristiansen G, Bootz F and Dietrich D: Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma. PLoS One. 12:e01794122017. View Article : Google Scholar : PubMed/NCBI

Prochnow S, Wilczak W, Bosch V, Clauditz TS and Muenscher A: ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma. Clin Oral Investig. 23:3319–3329. 2019. View Article : Google Scholar

Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S and Martins RG: ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: Results from a randomised, phase II trial. Br J Cancer. 109:2096–2105. 2013. View Article : Google Scholar : PubMed/NCBI

da Costa AA, D'Almeida Costa F, Ribeiro AR, Guimarães AP, Chinen LT, Lopes CA and de Lima VC: Low PTEN expression is associated with worse overall survival in head and neck squamous cell carcinoma patients treated with chemotherapy and cetuximab. Int J Clin Oncol. 20:282–289. 2015. View Article : Google Scholar

Slavik M, Shatokhina T, Sana J, Ahmad P, Kazda T, Selingerova I, Hermanova M, Cervena R, Novotny T, Burkon P, et al: Expression of CD44, EGFR, p16, and their mutual combinations in patients with head and neck cancer: Impact on outcomes of intensity-modulated radiation therapy. Head Neck. 41:940–949. 2019. View Article : Google Scholar

Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X and Wu K: Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer. 17:129. 2018. View Article : Google Scholar : PubMed/NCBI

Li X, Shao C, Shi Y and Han W: Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 11:312018. View Article : Google Scholar : PubMed/NCBI

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al: PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI

Ribas A: Adaptive immune resistance: How cancer protects from immune attack. Cancer Discov. 5:915–919. 2015. View Article : Google Scholar : PubMed/NCBI

Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, et al: TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. ESMO Open. 3:e0002572018. View Article : Google Scholar : PubMed/NCBI

Ling DC, Bakkenist CJ, Ferris RL and Clump DA: Role of immunotherapy in head and neck cancer. Semin Radiat Oncol. 28:12–16. 2018. View Article : Google Scholar

Knocke S, Fleischmann-Mundt B, Saborowski M, Manns MP, Kühnel F, Wirth TC and Woller N: Tailored tumor immunogenicity reveals regulation of CD4 and CD8 T cell responses against cancer. Cell Rep. 17:2234–2246. 2016. View Article : Google Scholar : PubMed/NCBI

de Ruiter EJ, Ooft ML, Devriese LA and Willems SM: The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncoimmunology. 6:e13561482017. View Article : Google Scholar : PubMed/NCBI

Gooden MJ, de Bock GH, Leffers N, Daemen T and Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI

Noble F, Mellows T, McCormick Matthews LH, Bateman AC, Harris S, Underwood TJ, Byrne JP, Bailey IS, Sharland DM, Kelly JJ, et al: Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunol Immunother. 65:651–662. 2016. View Article : Google Scholar : PubMed/NCBI

Xu P, Fan W, Zhang Z, Wang J, Wang P, Li Y and Yu M: The clinicopathological and prognostic implications of FoxP3⁺ Regulatory T cells in patients with colorectal cancer: A meta-analysis. Front Physiol. 8:9502017. View Article : Google Scholar

Weller P, Bankfalvi A, Gu X, Dominas N, Lehnerdt GF, Zeidler R, Lang S, Brandau S and Dumitru CA: The role of tumour FoxP3 as prognostic marker in different subtypes of head and neck cancer. Eur J Cancer. 50:1291–1300. 2014. View Article : Google Scholar : PubMed/NCBI

Seminerio I, Descamps G, Dupont S, de Marrez L, Laigle JA, Lechien JR, Kindt N, Journe F and Saussez S: Infiltration of FoxP3+ Regulatory T cells is a strong and independent prognostic factor in head and neck squamous cell carcinoma. Cancers (Basel). 11:2272019. View Article : Google Scholar

Echarti A, Hecht M, Büttner-Herold M, Haderlein M, Hartmann A, Fietkau R and Distel L: CD8+ and regulatory T cells differentiate tumor immune phenotypes and predict survival in locally advanced head and neck cancer. Cancers (Basel). 11:13982019. View Article : Google Scholar

Cho JH and Lim YC: Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncol. 112:1050842021. View Article : Google Scholar

Lukesova E, Boucek J, Rotnaglova E, Salakova M, Koslabova E, Grega M, Eckschlager T, Rihova B, Prochazka B, Klozar J and Tachezy R: High level of tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas. Biomed Res Int. 2014:3039292014. View Article : Google Scholar : PubMed/NCBI

Pedroza-Pacheco I, Madrigal A and Saudemont A: Interaction between natural killer cells and regulatory T cells: Perspectives for immunotherapy. Cell Mol Immunol. 10:222–229. 2013. View Article : Google Scholar : PubMed/NCBI

Renoux VM, Bisig B, Langers I, Dortu E, Clémenceau B, Thiry M, Deroanne C, Colige A, Boniver J, Delvenne P and Jacobs N: Human papillomavirus entry into NK cells requires CD16 expression and triggers cytotoxic activity and cytokine secretion. Eur J Immunol. 41:3240–3252. 2011. View Article : Google Scholar : PubMed/NCBI

Wolf GT, Chepeha DB, Bellile E, Nguyen A, Thomas D and McHugh J: University of Michigan Head and Neck SPORE Program: Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary study. Oral Oncol. 51:90–95. 2015. View Article : Google Scholar

Desrichard A, Kuo F, Chowell D, Lee KW, Riaz N, Wong RJ, Chan TA and Morris LGT: Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas. J Natl Cancer Inst. 110:1386–1392. 2018. View Article : Google Scholar : PubMed/NCBI

Choi Y, Shi Y, Haymaker CL, Naing A, Ciliberto G and Hajjar J: T-cell agonists in cancer immunotherapy. J Immunother Cancer. 8:e0009662020. View Article : Google Scholar : PubMed/NCBI

Mahoney KM, Rennert PD and Freeman GJ: Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 14:561–584. 2015. View Article : Google Scholar : PubMed/NCBI

Stämpfli MR and Anderson GP: How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 9:377–384. 2009. View Article : Google Scholar : PubMed/NCBI

Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348:124–128. 2015. View Article : Google Scholar : PubMed/NCBI

de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, et al: Effects of tobacco smoking on the tumor immune microenvironment in Head and Neck squamous cell carcinoma. Clin Cancer Res. 26:1474–1485. 2020. View Article : Google Scholar :

Yarchoan M, Hopkins A and Jaffee EM: Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI

Seiwert TY, Haddad R, Bauml J, Weiss J, Pfister DG, Gupta S, Mehra R, Gluck I, Kang H, Worden F, et al: Abstract LB-339: Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC). Cancer Res. 78:LB-339. 2018.

Hanna GJ, Lizotte P, Cavanaugh M, Kuo FC, Shivdasani P, Frieden A, Chau NG, Schoenfeld JD, Lorch JH, Uppaluri R, et al: Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 3:e988112018. View Article : Google Scholar

Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, et al: Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 51:202–206. 2019. View Article : Google Scholar : PubMed/NCBI

Li W, Wildsmith S, Ye J, Si H, Morsli N, He P, Shetty J, Yovine AJ, Holoweckyj N, Raja R, et al: Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure. J Clin Oncol. 38:65112020. View Article : Google Scholar

Alexandrov LB, Ju YS, Haase K, Van Loo P, Martincorena I, Nik-Zainal S, Totoki Y, Fujimoto A, Nakagawa H, Shibata T, et al: Mutational signatures associated with tobacco smoking in human cancer. Science. 354:618–622. 2016. View Article : Google Scholar : PubMed/NCBI

Gajewski TF: The next hurdle in cancer immunotherapy: Overcoming the Non-T-Cell-inflamed tumor microenvironment. Semin Oncol. 42:663–671. 2015. View Article : Google Scholar : PubMed/NCBI

Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, et al: PD-1 blockade expands intratumoral Memory T cells. Cancer Immunol Res. 4:194–203. 2016. View Article : Google Scholar : PubMed/NCBI

Gavrielatou N, Doumas S, Economopoulou P, Foukas PG and Psyrri A: Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev. 84:1019772020. View Article : Google Scholar : PubMed/NCBI

Jia YQ, Yang B, Wen LL, Mu WX, Wang Z and Cheng B: Prognostic value of immune checkpoint molecules in head and neck cancer: A meta-analysis. Aging. 11:501–522. 2019. View Article : Google Scholar : PubMed/NCBI

Botticelli A, Cerbelli B, Lionetto L, Zizzari I, Salati M, Pisano A, Federica M, Simmaco M, Nuti M and Marchetti P: Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC? J Transl Med. 16:2192018. View Article : Google Scholar : PubMed/NCBI

Lin DJ, Ng JCK, Huang L, Robinson M, O'Hara J, Wilson JA and Mellor AL: The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review. Clin Otolaryngol. 46:919–934. 2021. View Article : Google Scholar : PubMed/NCBI

Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, Treue D, Stenzinger A, Glimm H, Fröhling S, Kindler T, Brandts CH, et al: Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. Int J Cancer. 147:2293–2302. 2020. View Article : Google Scholar : PubMed/NCBI

Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, et al: Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: Implications for immunotherapy. Ann Oncol. 30:68–75. 2019. View Article : Google Scholar

Brierley JD, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. John Wiley & Sons; 2017

Wondergem NE, Nijenhuis DNLM, Poell JB, Leemans CR, Brakenhoff RH and van de Ven R: At the crossroads of molecular biology and immunology: Molecular pathways for immunological targeting of head and neck squamous cell carcinoma. Front Oral Health. 2:6479802021. View Article : Google Scholar

Spranger S and Gajewski TF: Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 18:139–147. 2018. View Article : Google Scholar : PubMed/NCBI

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6:202–216. 2016. View Article : Google Scholar :

Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, et al: PI3K inhibition reduces mammary tumor growth and facilitates anti-tumor immunity and Anti-PD1 responses. Clin Cancer Res. 23:3371–3384. 2017. View Article : Google Scholar :

Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y and Hu LL: ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 19:1997–2007. 2020.PubMed/NCBI

Ngan HL, Liu Y, Fong AY, Poon PHY, Yeung CK, Chan SSM, Lau A, Piao W, Li H, Tse JSW, et al: MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life Sci Alliance. 3:e2019005452020. View Article : Google Scholar : PubMed/NCBI

de Ruiter EJ, Ooft ML, Devriese LA and Willems SM: The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Oncoimmunology. 6:e13561482017. View Article : Google Scholar : PubMed/NCBI

Takikita M, Xie R, Chung JY, Cho H, Ylaya K, Hong SM, Moskaluk CA and Hewitt SM: Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma. J Transl Med. 9:1262011. View Article : Google Scholar : PubMed/NCBI

Motedayen Aval L, Pease JE, Sharma R and Pinato DJ: Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med. 9:33232020. View Article : Google Scholar :

Zandberg D, Ferris R, Laux D, Mehra R, Nabell L, Kaczmar J, Gibson MK, Kim YJ, Neupane P, Bauman J, et al: 71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results. Ann Oncol. 31:S1446–S1447. 2020. View Article : Google Scholar

Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, Trotter BW, Altman MD, Buevich AV, Cash B, et al: An orally available non-nucleotide STING agonist with antitumor activity. Science. 369:eaba60982020. View Article : Google Scholar : PubMed/NCBI

Chin EN, Yu C, Vartabedian VF, Jia Y, Kumar M, Gamo AM, Vernier W, Ali SH, Kissai M, Lazar DC, et al: Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science. 369:993–999. 2020. View Article : Google Scholar : PubMed/NCBI

Zander H, Müller-Egert S, Zwiewka M, Groß S, van Zandbergen G and Engelbergs J: Checkpoint inhibitors for cancer therapy. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 63:1322–1330. 2020.In German. View Article : Google Scholar : PubMed/NCBI

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet. 393:156–167. 2019. View Article : Google Scholar

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019. View Article : Google Scholar : PubMed/NCBI

Prasad V and Kaestner V: Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 44:132–135. 2017. View Article : Google Scholar : PubMed/NCBI

Fessas P, Lee H, Ikemizu S and Janowitz T: A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 44:136–140. 2017. View Article : Google Scholar : PubMed/NCBI

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, et al: Pembrolizumab for Platinum-and Cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study. J Clin Oncol. 35:1542–1549. 2017. View Article : Google Scholar : PubMed/NCBI

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, et al: Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 81:45–51. 2018. View Article : Google Scholar : PubMed/NCBI

Rasmussen JH, Lelkaitis G, Håkansson K, Vogelius IR, Johannesen HH, Fischer BM, Bentzen SM, Specht L, Kristensen CA, von Buchwald C, et al: Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. Br J Cancer. 120:1003–1006. 2019. View Article : Google Scholar : PubMed/NCBI

Moratin J, Metzger K, Safaltin A, Herpel E, Hoffmann J, Freier K, Hess J and Horn D: Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Head Neck. 41:2484–2491. 2019. View Article : Google Scholar : PubMed/NCBI

Feng Y, Jin H, Guo K, Xiang Y, Zhang Y, Du W, Shen M and Ruan S: Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 inhibitors in malignant cancer patients: Does PD-L1 matter? Front Pharmacol. 12:572845. 2021. View Article : Google Scholar : PubMed/NCBI

Tardy MP, Di Mauro I, Ebran N, Refae S, Bozec A, Benezery K, Peyrade F, Guigay J, Sudaka-Bahadoran A, Badoual C, et al: Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma. Oral Oncol. 80:104–107. 2018. View Article : Google Scholar : PubMed/NCBI

Evrard D, Hourseau M, Couvelard A, Paradis V, Gauthier H, Raymond E, Halimi C, Barry B and Faivre S: PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma. Oncoimmunology. 9:18444032020. View Article : Google Scholar : PubMed/NCBI

Nielsen C, Ohm-Laursen L, Barington T, Husby S and Lillevang ST: Alternative splice variants of the human PD-1 gene. Cell Immunol. 235:109–116. 2005. View Article : Google Scholar : PubMed/NCBI

Greisen SR, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, Hørslev-Petersen K, Hvid M and Deleuran B: Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand J Rheumatol. 43:101–108. 2014. View Article : Google Scholar

Zhu X and Lang J: Soluble PD-1 and PD-L1: Predictive and prognostic significance in cancer. Oncotarget. 8:97671–97682. 2017. View Article : Google Scholar : PubMed/NCBI

Wei W, Xu B, Wang Y and Wu C, Jiang J and Wu C: Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis. Medicine (Baltimore). 97:e96172018. View Article : Google Scholar

Wu P, Wu D, Li L, Chai Y and Huang J: PD-L1 and survival in solid tumors: A meta-analysis. PLoS One. 10:e01314032015. View Article : Google Scholar : PubMed/NCBI

Gandini S, Massi D and Mandalà M: PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 100:88–98. 2016. View Article : Google Scholar : PubMed/NCBI

Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, et al: Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann Oncol. 28:1923–1933. 2017. View Article : Google Scholar : PubMed/NCBI

Mildner F, Sopper S, Amann A, Pircher A, Pall G, Köck S, Naismith E, Wolf D and Gamerith G: Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC). Crit Rev Oncol Hematol. 153:1029482020. View Article : Google Scholar : PubMed/NCBI

Younis RH, Ghita I, Elnaggar M, Chaisuparat R, Theofilou VI, Dyalram D, Ord RA, Davila E, Tallon LJ, Papadimitriou JC, et al: Soluble Sema4D in plasma of head and neck squamous cell carcinoma patients is associated with underlying non-inflamed tumor profile. Front Immunol. 12:5966462021. View Article : Google Scholar : PubMed/NCBI

Leonard JE, Fisher TL, Winter LA, Cornelius CA, Reilly C, Smith ES and Zauderer M: Nonclinical safety evaluation of VX15/2503, a humanized IgG4 Anti-SEMA4D antibody. Mol Cancer Ther. 14:964–972. 2015. View Article : Google Scholar : PubMed/NCBI

Patnaik A, Weiss GJ, Leonard JE, Rasco DW, Sachdev JC, Fisher TL, Winter LA, Reilly C, Parker RB, Mutz D, et al: Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a First-In-Human study of patients with advanced solid tumors. Clin Cancer Res. 22:827–836. 2016. View Article : Google Scholar

Boschert V, Teusch J, Aljasem A, Schmucker P, Klenk N, Straub A, Bittrich M, Seher A, Linz C, Müller-Richter UDA and Hartmann S: HGF-Induced PD-L1 expression in head and neck cancer: Preclinical and clinical findings. Int J Mol Sci. 21:87702020. View Article : Google Scholar :

Freeman GJ, Sharpe AH and Kuchroo VK: Protect the killer: CTLs need defenses against the tumor. Nat Med. 8:787–789. 2002. View Article : Google Scholar : PubMed/NCBI

Merhi M, Raza A, Inchakalody V, Zar AR, Uddin S and Dermime S: Immunotherapeutic strategies in patients with advanced head and neck squamous cell carcinoma. Ann Transl Med. 7(Suppl 1): S222019. View Article : Google Scholar : PubMed/NCBI

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI

Rodrigues J, Heinrich MA, Teixeira LM and Prakash J: 3D in vitro model (R)evolution: Unveiling tumor-stroma interactions. Trends Cancer. 7:249–264. 2021. View Article : Google Scholar

Halfter K, Ditsch N, Kolberg HC, Fischer H, Hauzenberger T, von Koch FE, Bauerfeind I, von Minckwitz G, Funke I, Crispin A, et al: Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy-the SpheroNEO study. BMC Cancer. 15:5192015. View Article : Google Scholar

Bauml JM, Aggarwal C and Cohen RB: Immunotherapy for head and neck cancer: Where are we now and where are we going? Ann Transl Med. 7(Suppl 3): S752019. View Article : Google Scholar : PubMed/NCBI

Hoarau-Véchot J, Rafii A, Touboul C and Pasquier J: Halfway between 2D and Animal Models: Are 3D Cultures the ideal tool to study cancer-microenvironment interactions? Int J Mol Sci. 19:1812018. View Article : Google Scholar :

Marrella A, Dondero A, Aiello M, Casu B, Olive D, Regis S, Bottino C, Pende D, Meazza R, Caluori G, et al: Cell-laden hydrogel as a clinical-relevant 3D model for analyzing neuro-blastoma growth, immunophenotype, and susceptibility to therapies. Front Immunol. 10:18762019. View Article : Google Scholar

Appleton KM, Elrod AK, Lassahn KA, Shuford S, Holmes LM and DesRochers TM: PD-1/PD-L1 checkpoint inhibitors in combination with olaparib display antitumor activity in ovarian cancer patient-derived three-dimensional spheroid cultures. Cancer Immunol Immunother. 70:843–856. 2021. View Article : Google Scholar : PubMed/NCBI

Weiswald LB, Richon S, Massonnet G, Guinebretière JM, Vacher S, Laurendeau I, Cottu P, Marangoni E, Nemati F, Validire P, et al: A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. Br J Cancer. 108:1720–1731. 2013. View Article : Google Scholar : PubMed/NCBI

Weiswald LB, Richon S, Validire P, Briffod M, Lai-Kuen R, Cordelières FP, Bertrand F, Dargere D, Massonnet G, Marangoni E, et al: Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness. Br J Cancer. 101:473–482. 2009. View Article : Google Scholar : PubMed/NCBI

Jiang X, Seo YD, Chang JH, Coveler A, Nigjeh EN, Pan S, Jalikis F, Yeung RS, Crispe IN and Pillarisetty VG: Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. Oncoimmunology. 6:e13332102017. View Article : Google Scholar : PubMed/NCBI

Herter S, Morra L, Schlenker R, Sulcova J, Fahrni L, Waldhauer I, Lehmann S, Reisländer T, Agarkova I, Kelm JM, et al: A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents. Cancer Immunol Immunother. 66:129–140. 2017. View Article : Google Scholar :

Larkins E, Blumenthal GM, Yuan W, He K, Sridhara R, Subramaniam S, Zhao H, Liu C, Yu J, Goldberg KB, et al: FDA approval summary: Pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist. 22:873–878. 2017. View Article : Google Scholar : PubMed/NCBI

Collins A, Miles GJ, Wood J, MacFarlane M, Pritchard C and Moss E: Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer. Gynecol Oncol. 156:251–259. 2020. View Article : Google Scholar

Seo YD, Jiang X, Sullivan KM, Jalikis FG, Smythe KS, Abbasi A, Vignali M, Park JO, Daniel SK, Pollack SM, et al: Mobilization of CD8⁺ T cells via CXCR4 blockade facilitates PD-1 checkpoint therapy in human pancreatic cancer. Clin Cancer Res. 25:3934–3945. 2019. View Article : Google Scholar : PubMed/NCBI

Muthuswamy R, Corman JM, Dahl K, Chatta GS and Kalinski P: Functional reprogramming of human prostate cancer to promote local attraction of effector CD8⁺ T cells. Prostate. 76:1095–1105. 2016. View Article : Google Scholar : PubMed/NCBI

Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, Slagter M, van der Velden DL, Kaing S, Kelderman S, et al: Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 174:1586–1598.e2. 2018. View Article : Google Scholar : PubMed/NCBI

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, et al: Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov. 8:196–215. 2018. View Article : Google Scholar :

Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, et al: Organoid modeling of the tumor immune microenvironment. Cell. 175:1972–1988.e16. 2018. View Article : Google Scholar : PubMed/NCBI

Augustine TN, Dix-Peek T, Duarte R and Candy GP: Establishment of a heterotypic 3D culture system to evaluate the interaction of TREG lymphocytes and NK cells with breast cancer. J Immunol Methods. 426:1–13. 2015. View Article : Google Scholar : PubMed/NCBI

Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H, Dhandapani M, Brijwani N, Pinto DD, Prasath A, Shanthappa BU, et al: Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat Commun. 6:61692015. View Article : Google Scholar : PubMed/NCBI

Al-Samadi A, Poor B, Tuomainen K, Liu V, Hyytiäinen A, Suleymanova I, Mesimaki K, Wilkman T, Mäkitie A, Saavalainen P and Salo T: In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients. Exp Cell Res. 383:1115082019. View Article : Google Scholar : PubMed/NCBI

Aref AR, Campisi M, Ivanova E, Portell A, Larios D, Piel BP, Mathur N, Zhou C, Coakley RV, Bartels A, et al: 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip. 18:3129–3143. 2018. View Article : Google Scholar : PubMed/NCBI

Engelmann L, Thierauf J, Koerich Laureano N, Stark HJ, Prigge ES, Horn D, Freier K, Grabe N, Rong C, Federspil P, et al: Organotypic Co-cultures as a Novel 3D model for head and neck squamous cell carcinoma. Cancers (Basel). 12:23302020. View Article : Google Scholar

Kross KW, Heimdal JH, Olsnes C, Olofson J and Aarstad HJ: Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue. Acta Otolaryngol. 127:532–539. 2007. View Article : Google Scholar : PubMed/NCBI

Klöss S, Chambron N, Gardlowski T, Weil S, Koch J, Esser R, Pogge von Strandmann E, Morgan MA, Arseniev L, Seitz O and Köhl U: Cetuximab reconstitutes pro-inflammatory cytokine secretions and tumor-infiltrating capabilities of sMICA-inhibited NK cells in HNSCC tumor spheroids. Front Immunol. 6:5432015. View Article : Google Scholar : PubMed/NCBI

Bougherara H, Mansuet-Lupo A, Alifano M, Ngô C, Damotte D, Le Frère-Belda MA, Donnadieu E and Peranzoni E: Real-time imaging of resident T cells in human lung and ovarian carcinomas reveals how different tumor microenvironments control T lymphocyte migration. Front Immunol. 6:5002015. View Article : Google Scholar : PubMed/NCBI

Laudanski K, Stentz M, DiMeglio M, Furey W, Steinberg T and Patel A: Potential Pitfalls of the Humanized Mice in Modeling Sepsis. Int J Inflam. 2018:65634542018.PubMed/NCBI

Osuchowski MF, Remick DG, Lederer JA, Lang CH, Aasen AO, Aibiki M, Azevedo LC, Bahrami S, Boros M, Cooney R, et al: Abandon the mouse research ship? Not just yet! Shock. 41:463–475. 2014. View Article : Google Scholar

Mestas J and Hughes CW: Of mice and not men: Differences between mouse and human immunology. J Immunol. 172:2731–2738. 2004. View Article : Google Scholar : PubMed/NCBI

Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, et al: Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA. 110:3507–3512. 2013. View Article : Google Scholar : PubMed/NCBI

Mak IW, Evaniew N and Ghert M: Lost in translation: Animal models and clinical trials in cancer treatment. Am J Transl Res. 6:114–118. 2014.PubMed/NCBI

Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P and Khan KS: Comparison of treatment effects between animal experiments and clinical trials: Systematic review. BMJ. 334:1972007. View Article : Google Scholar :

Hackam DG and Redelmeier DA: Translation of research evidence from animals to humans. JAMA. 296:1731–1732. 2006. View Article : Google Scholar : PubMed/NCBI

Nauseef WM: The proper study of mankind. J Clin Invest. 107:401–403. 2001. View Article : Google Scholar : PubMed/NCBI

McGonigle P and Ruggeri B: Animal models of human disease: Challenges in enabling translation. Biochem Pharmacol. 87:162–171. 2014. View Article : Google Scholar

Green SB: Can animal data translate to innovations necessary for a new era of patient-centred and individualised healthcare? Bias in preclinical animal research. BMC Med Ethics. 16:53. 2015. View Article : Google Scholar : PubMed/NCBI

Hameed I and Gaudino M: Commentary: Do not kill (especially for nothing). J Thoracic Cardiovascular Surg. 158:1557–1558. 2019. View Article : Google Scholar

Leenaars CHC, Kouwenaar C, Stafleu FR, Bleich A, Ritskes-Hoitinga M, De Vries RBM and Meijboom FLB: Animal to human translation: A systematic scoping review of reported concordance rates. J Transl Med. 17:2232019. View Article : Google Scholar : PubMed/NCBI

Ruggeri BA, Camp F and Miknyoczki S: Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol. 87:150–161. 2014. View Article : Google Scholar

Van Norman GA: Limitations of animal studies for predicting toxicity in clinical trials: Is it time to rethink our current approach? JACC Basic Transl Sci. 4:845–854. 2019. View Article : Google Scholar

Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA and Egger M: Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet. 364:2021–2029. 2004. View Article : Google Scholar : PubMed/NCBI

Knobloch J, Jungck D and Koch A: The molecular mechanisms of thalidomide teratogenicity and implications for modern medicine. Curr Mol Med. 17:108–117. 2017. View Article : Google Scholar : PubMed/NCBI

O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH and Howells DW: 1,026 experimental treatments in acute stroke. Ann Neurol. 59:467–477. 2006. View Article : Google Scholar : PubMed/NCBI

Akhtar A: The flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 24:407–419. 2015. View Article : Google Scholar : PubMed/NCBI

Pound P, Ebrahim S, Sandercock P, Bracken MB and Roberts I: Where is the evidence that animal research benefits humans? BMJ. 328:514–517. 2004. View Article : Google Scholar : PubMed/NCBI

DeVita VT and Chu E: A history of cancer chemotherapy. Cancer Res. 68:8643–8653. 2008. View Article : Google Scholar : PubMed/NCBI

Saito R, Kobayashi T, Kashima S, Matsumoto K and Ogawa O: Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. Int J Clin Oncol. 25:831–841. 2020. View Article : Google Scholar

Zheng D, Liwinski T and Elinav E: Interaction between microbiota and immunity in health and disease. Cell Res. 30:492–506. 2020. View Article : Google Scholar : PubMed/NCBI

Affolter A, Lammert A, Kern J, Scherl C and Rotter N: Precision medicine gains momentum: Novel 3D models and stem cell-based approaches in head and neck cancer. Front Cell Dev Biol. 9:6665152021. View Article : Google Scholar : PubMed/NCBI

Bauer H, Horowitz RE, Levenson SM and Popper H: The response of the lymphatic tissue to the microbial flora. Studies on germfree mice. Am J Pathol. 42:471–483. 1963.PubMed/NCBI

Li J, Huang J, Jeong JH, Park SJ, Wei R, Peng J, Luo Z, Chen YT, Feng Y and Luo JL: Selective TBK1/IKKi dual inhibitors with anticancer potency. Int J Cancer. 134:1972–1980. 2014. View Article : Google Scholar

Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, et al: Cross-talk signaling between HER3 and HPV16 E6 and E7 mediates resistance to PI3K inhibitors in head and neck cancer. Cancer Res. 78:2383–2395. 2018. View Article : Google Scholar : PubMed/NCBI

Bais MV, Kukuruzinska M and Trackman PC: Orthotopic non-metastatic and metastatic oral cancer mouse models. Oral Oncol. 51:476–482. 2015. View Article : Google Scholar : PubMed/NCBI

Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, et al: Human papillomavirus regulates HER3 expression in head and neck cancer: Implications for targeted HER3 therapy in HPV(+) patients. Clin Cancer Res. 23:3072–3083. 2017. View Article : Google Scholar :

Rossa C Jr and D'Silva NJ: Immune-relevant aspects of murine models of head and neck cancer. Oncogene. 38:3973–3988. 2019. View Article : Google Scholar : PubMed/NCBI

Olson B, Li Y, Lin Y, Liu ET and Patnaik A: Mouse Models for Cancer Immunotherapy Research. Cancer Discov. 8:1358–1365. 2018. View Article : Google Scholar : PubMed/NCBI

Li E, Lin L, Chen CW and Ou DL: Mouse models for immunotherapy in hepatocellular carcinoma. Cancers (Basel). 11:18002019. View Article : Google Scholar

Jiao R, Allen KJH, Malo ME, Rickles D and Dadachova E: Evaluating the combination of radioimmunotherapy and immunotherapy in a melanoma mouse model. Int J Mol Sci. 21:7732020. View Article : Google Scholar :

Kim SS, Harford JB, Moghe M, Slaughter T, Doherty C and Chang EH: A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma. Int J Cancer. 145:2535–2546. 2019. View Article : Google Scholar : PubMed/NCBI

Chulpanova DS, Kitaeva KV, Rutland CS, Rizvanov AA and Solovyeva VV: Mouse tumor models for advanced cancer immunotherapy. Int J Mol Sci. 21:41182020. View Article : Google Scholar :

Yu JW, Bhattacharya S, Yanamandra N, Kilian D, Shi H, Yadavilli S, Katlinskaya Y, Kaczynski H, Conner M, Benson W, et al: Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS One. 13:e02062232018. View Article : Google Scholar : PubMed/NCBI

Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Luis Callejas-Valera J, Vitale-Cross L, Martin D, Amornphimoltham P, Mcdermott J, et al: Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4. Nat Commun. 10:55462019. View Article : Google Scholar : PubMed/NCBI

Rangarajan A and Weinberg RA: Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat Rev Cancer. 3:952–959. 2003. View Article : Google Scholar

O'Malley BW Jr, Cope KA, Johnson CS and Schwartz MR: A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg. 123:20–24. 1997. View Article : Google Scholar : PubMed/NCBI

Kim S: Animal models of cancer in the head and neck region. Clin Exp Otorhinolaryngol. 2:55–60. 2009. View Article : Google Scholar : PubMed/NCBI

Vahle AK, Kerem A, Oztürk E, Bankfalvi A, Lang S and Brandau S: Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice-role of toll-like-receptor 4 expressed on host cells. Cancer Lett. 317:199–206. 2012. View Article : Google Scholar

Kersten K, de Visser KE, van Miltenburg MH and Jonkers J: Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 9:137–153. 2017. View Article : Google Scholar :

Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, Wolford C, Phillips G, Caligiuri MA, Zheng P and Liu Y: Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood. 106:3127–3133. 2005. View Article : Google Scholar : PubMed/NCBI

Sanmamed MF, Chester C, Melero I and Kohrt H: Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. Ann Oncol. 27:1190–1198. 2016. View Article : Google Scholar : PubMed/NCBI

Sánchez-Rivera FJ and Jacks T: Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer. 15:387–393. 2015. View Article : Google Scholar : PubMed/NCBI

Azangou-Khyavy M, Ghasemi M, Khanali J, Boroomand-Saboor M, Jamalkhah M, Soleimani M and Kiani J: CRISPR/Cas: From tumor gene editing to T Cell-based immunotherapy of cancer. Front Immunol. 11:20622020. View Article : Google Scholar : PubMed/NCBI

Ren J, Liu X, Fang C, Jiang S, June CH and Zhao Y: Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 23:2255–2266. 2017. View Article : Google Scholar :

Cyranoski D: CRISPR gene-editing tested in a person for the first time. Nature. 539:4792016. View Article : Google Scholar : PubMed/NCBI

Kelland LR: Of mice and men: Values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer. 40:827–836. 2004. View Article : Google Scholar : PubMed/NCBI

Pelleitier M and Montplaisir S: The nude mouse: A model of deficient T-cell function. Methods Achiev Exp Pathol. 7:149–166. 1975.PubMed/NCBI

Dixon TC, Meselson M, Guillemin J and Hanna PC: Anthrax. N Engl J Med. 341:815–826. 1999. View Article : Google Scholar : PubMed/NCBI

Watts CJ, Hahn BL and Sohnle PG: Resistance of athymic nude mice to experimental cutaneous Bacillus anthracis infection. J Infect Dis. 199:673–679. 2009. View Article : Google Scholar : PubMed/NCBI

Kang Y: Analysis of cancer stem cell metastasis in xenograft animal models. Methods Mol Biol. 568:7–19. 2009. View Article : Google Scholar : PubMed/NCBI

Nauta JM, Roodenburg JL, Nikkels PG, Witjes MJ and Vermey A: Comparison of epithelial dysplasia-the 4NQO rat palate model and human oral mucosa. Int J Oral Maxillofac Surg. 24:53–58. 1995. View Article : Google Scholar : PubMed/NCBI

Aromando RF, Pérez MA, Heber EM, Trivillin VA, Tomasi VH, Schwint AE and Itoiz ME: Potential role of mast cells in hamster cheek pouch carcinogenesis. Oral Oncol. 44:1080–1087. 2008. View Article : Google Scholar : PubMed/NCBI

Ghiabi M, Gallagher GT and Wong DT: Eosinophils, tissue eosinophilia, and eosinophil-derived transforming growth factor alpha in hamster oral carcinogenesis. Cancer Res. 52:389–393. 1992.PubMed/NCBI

Barker CF and Billingham RE: The lymphatic status of hamster cheek pouch tissue in relation to its properties as a graft and as a graft site. J Exp Med. 133:620–639. 1971. View Article : Google Scholar : PubMed/NCBI

Li Q, Dong H, Yang G, Song Y, Mou Y and Ni Y: Mouse tumor-bearing models as preclinical study platforms for oral squamous cell carcinoma. Front Oncol. 10:2122020. View Article : Google Scholar : PubMed/NCBI

Liu YC, Ho HC, Lee MR, Lai KC, Yeh CM, Lin YM, Ho TY, Hsiang CY and Chung JG: Early induction of cytokines/cytokine receptors and Cox2, and activation of NF-κB in 4-nitroquino-line 1-oxide-induced murine oral cancer model. Toxicol Appl Pharmacol. 262:107–116. 2012. View Article : Google Scholar : PubMed/NCBI

Eveson JW and MacDonald DG: Hamster tongue carcinogenesis. I. Characteristics of the experimental model. J Oral Pathol. 10:322–331. 1981. View Article : Google Scholar : PubMed/NCBI

Chen YF, Chang KW, Yang IT, Tu HF and Lin SC: Establishment of syngeneic murine model for oral cancer therapy. Oral Oncol. 95:194–201. 2019. View Article : Google Scholar : PubMed/NCBI

Bürtin F, Mullins CS and Linnebacher M: Mouse models of colorectal cancer: Past, present and future perspectives. World J Gastroenterol. 26:1394–1426. 2020. View Article : Google Scholar : PubMed/NCBI

Durinikova E, Buzo K and Arena S: Preclinical models as patients' avatars for precision medicine in colorectal cancer: Past and future challenges. J Exp Clin Cancer Res. 40:1852021. View Article : Google Scholar : PubMed/NCBI

Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, et al: A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 7:776–790. 2013. View Article : Google Scholar : PubMed/NCBI

Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, et al: Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 17:5793–5800. 2011. View Article : Google Scholar : PubMed/NCBI

Choi Y, Lee S, Kim K, Kim SH, Chung YJ and Lee C: Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp Mol Med. 50:1–9. 2018. View Article : Google Scholar : PubMed/NCBI

Choi SY, Lin D, Gout PW, Collins CC, Xu Y and Wang Y: Lessons from patient-derived xenografts for better in vitro modeling of human cancer. Adv Drug Deliv Rev. 79-80:222–237. 2014. View Article : Google Scholar : PubMed/NCBI

Facompre ND, Sahu V, Montone KT, Harmeyer KM, Nakagawa H, Rustgi AK, Weinstein GS, Gimotty PA and Basu D: Barriers to generating PDX models of HPV-related head and neck cancer. Laryngoscope. 127:2777–2783. 2017. View Article : Google Scholar : PubMed/NCBI

Mosier DE, Gulizia RJ, Baird SM and Wilson DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 335:256–259. 1988. View Article : Google Scholar : PubMed/NCBI

Ali N, Flutter B, Sanchez Rodriguez R, Sharif-Paghaleh E, Barber LD, Lombardi G and Nestle FO: Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγ null mice display a T-effector memory phenotype. PLoS One. 7:e442192012. View Article : Google Scholar

Lan P, Tonomura N, Shimizu A, Wang S and Yang YG: Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood. 108:487–492. 2006. View Article : Google Scholar : PubMed/NCBI

Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, et al: Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4:998–1013. 2014. View Article : Google Scholar : PubMed/NCBI

Matsumura T, Kametani Y, Ando K, Hirano Y, Katano I, Ito R, Shiina M, Tsukamoto H, Saito Y, Tokuda Y, et al: Functional CD5+ B cells develop predominantly in the spleen of NOD/SCID/gammac(null) (NOG) mice transplanted either with human umbilical cord blood, bone marrow, or mobilized peripheral blood CD34⁺ cells. Exp Hematol. 31:789–797. 2003. View Article : Google Scholar : PubMed/NCBI

Hanazawa A, Ito R, Katano I, Kawai K, Goto M, Suemizu H, Kawakami Y, Ito M and Takahashi T: Generation of Human immunosuppressive myeloid cell populations in human Interleukin-6 transgenic NOG mice. Front Immunol. 9:1522018. View Article : Google Scholar : PubMed/NCBI

Pan B, Wei X and Xu X: Patient-derived xenograft models in hepatopancreatobiliary cancer. Cancer Cell Int. 22:41. 2022. View Article : Google Scholar : PubMed/NCBI

Stecklum M, Klinghammer K, Wulf-Goldenberg A, Brzezicha B, Jöhrens K and Hoffmann J: P0314 Preclinical case study: Patient-derived head and neck cancer xenograft on mice humanized with autologous immune cells, a model for personalized immuno-oncology research. J Immuno Ther Cancer. 8(Suppl 2): A27–A28. 2020.

Morton JJ, Bird G, Keysar SB, Astling DP, Lyons TR, Anderson RT, Glogowska MJ, Estes P, Eagles JR, Le PN, et al: XactMice: Humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. Oncogene. 35:290–300. 2016. View Article : Google Scholar

DeBord LC, Pathak RR, Villaneuva M, Liu HC, Harrington DA, Yu W, Lewis MT and Sikora AG: The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. Am J Cancer Res. 8:1642–1660. 2018.PubMed/NCBI

Mapanao AK, Che PP, Sarogni P, Sminia P, Giovannetti E and Voliani V: Tumor grafted-chick chorioallantoic membrane as an alternative model for biological cancer research and conventional/nanomaterial-based theranostics evaluation. Expert Opin Drug Metab Toxicol. 17:947–968. 2021. View Article : Google Scholar : PubMed/NCBI

Garcia P, Wang Y, Viallet J and Macek Jilkova Z: The chicken embryo model: A novel and relevant model for immune-based studies. Front Immunol. 12:7910812021. View Article : Google Scholar : PubMed/NCBI

Rousset X, Dosda E and Viallet J: Use of an egg grafted with tumor cells in order to study the anti-cancer effectiveness of immune therapies in the absence of immune effector cells other than those in the grafted egg. Google Patents. 2020.

Moticka EJ: Development of immunological competence in chickens. Am Z. 15:135–146. 1975. View Article : Google Scholar

Schmitd LB, Liu M, Scanlon CS, Banerjee R and D'Silva NJ: The chick chorioallantoic membrane in vivo model to assess perineural invasion in head and neck cancer. J Vis Exp. Jun 21–2019.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

de Medeiros MC, Liu M, Banerjee R, Bellile E, D'Silva NJ and Rossa C Jr: Galanin mediates tumor-induced immunosuppression in head and neck squamous cell carcinoma. Cell Oncol (Dordr). 45:241–256. 2022. View Article : Google Scholar

Gu L and Mooney DJ: Biomaterials and emerging anticancer therapeutics: Engineering the microenvironment. Nat Rev Cancer. 16:56–66. 2016. View Article : Google Scholar :

Kamatar A, Gunay G and Acar H: Natural and synthetic biomaterials for engineering multicellular tumor spheroids. Polymers (Basel). 12:25062020. View Article : Google Scholar

Park Y, Huh KM and Kang SW: Applications of biomaterials in 3D cell culture and contributions of 3D cell culture to drug development and basic biomedical research. Int J Mol Sci. 22:24912021. View Article : Google Scholar : PubMed/NCBI

Li J, Luo Y, Li B, Xia Y, Wang H and Fu C: Implantable and injectable biomaterial scaffolds for cancer immunotherapy. Front Bioeng Biotechnol. 8:6129502020. View Article : Google Scholar : PubMed/NCBI

Phuengkham H, Song C, Um SH and Lim YT: Implantable synthetic immune niche for spatiotemporal modulation of tumor-derived immunosuppression and systemic antitumor immunity: Postoperative immunotherapy. Adv Mater. 30:e17067192018. View Article : Google Scholar : PubMed/NCBI

Sanmamed MF and Chen L: A Paradigm shift in cancer immunotherapy: From enhancement to normalization. Cell. 175:313–326. 2018. View Article : Google Scholar : PubMed/NCBI

Datta P, Dey M, Ataie Z, Unutmaz D and Ozbolat IT: 3D bioprinting for reconstituting the cancer microenvironment. NPJ Precis Oncol. 4:182020. View Article : Google Scholar : PubMed/NCBI

Asghar W, El Assal R, Shafiee H, Pitteri S, Paulmurugan R and Demirci U: Engineering cancer microenvironments for in vitro 3-D tumor models. Mater Today (Kidlington). 18:539–553. 2015. View Article : Google Scholar

Oztan YC, Nawafleh N, Zhou Y, Liyanage PY, Hettiarachchi SD, Seven ES, Leblanc RM, Ouhtit A and Celik E: Recent advances on utilization of bioprinting for tumor modeling. Bioprinting. Jan 29–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

Swaminathan S and Clyne AM: Direct bioprinting of 3D multicellular breast spheroids onto endothelial networks. J Vis Exp. Nov 2–2020.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI

Browning JR, Derr P, Derr K, Doudican N, Michael S, Lish SR, Taylor NA, Krueger JG, Ferrer M, Carucci JA and Gareau DS: A 3D biofabricated cutaneous squamous cell carcinoma tissue model with multi-channel confocal microscopy imaging biomarkers to quantify antitumor effects of chemotherapeutics in tissue. Oncotarget. 11:2587–2596. 2020. View Article : Google Scholar : PubMed/NCBI

Almela T, Al-Sahaf S, Brook IM, Khoshroo K, Rasoulianboroujeni M, Fahimipour F, Tahriri M, Dashtimoghadam E, Bolt R, Tayebi L and Moharamzadeh K: 3D printed tissue engineered model for bone invasion of oral cancer. Tissue Cell. 52:71–77. 2018. View Article : Google Scholar : PubMed/NCBI

Matthews JB, Mason GI, Scully CM and Prime SS: In situ characterisation of the oral mucosal inflammatory cell response of rats induced by 4-nitroquinoline-N-oxide. Carcinogenesis. 7:783–788. 1986. View Article : Google Scholar : PubMed/NCBI

Thomas DW, Matthews JB, Patel V, Game SM and Prime SS: Inflammatory cell infiltrate associated with primary and transplanted tumours in an inbred model of oral carcinogenesis. J Oral Pathol Med. 24:23–31. 1995. View Article : Google Scholar : PubMed/NCBI